-
Brean Murray Carret: Growth Opportunities for NetApp
Wednesday, June 27, 2012 - 8:13am | 159According to a research report published this morning, Brean Murray Carret maintains its Hold rating for NetApp Inc (NASDAQ: NTAP). Brean Murray Carret mentions in the report, “We see potential revenue catalysts although headwinds. NTAP states it captured a record number of new customers in FY12,...
-
UPDATE: Brean Murray Carret & Co. Lowers PT on Synnex to $40
Tuesday, June 26, 2012 - 12:35pm | 148Brean Murray Carret & Co. reiterates a Buy rating on Synnex (NYSE: SNX) and lowers its price target from $45 to $40. Brean Murray Carret & Co. comments, “SNX's softer‐than‐Street May revenue and EPS guidance is actually within seasonal organic revenue norms (up 5% ‐ 6%) and also suggests Q...
-
UPDATE: Brean Murray Carret Lowers Synnex Price Target due to Disappointing Retail Sales
Tuesday, June 26, 2012 - 9:13am | 158According to a research report published this morning, Brean Murray Carret reiterates a Buy rating for Synnex Corporation (NYSE: SNX) and lowers its target price from $45 to $40. Brean Murray Carret mentions in the report, “SNX suspects retail PCs were hurt this Q by macro as well as 1) drive...
-
UPDATE: Brean Murray Carret Reiterates Buy rating on Keryx Biopharmaceuticals
Friday, June 22, 2012 - 9:26am | 146In a report published earlier today, Brean Murray Carret and Co. reiterates a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) and a price target of $5. Brean Murray Carret and Co. comments, “At Keryx's analyst day presentation, it announced plans for two more Zerenex trials, and gave a...
-
Benzinga's Downgrade Summary for June 20, 2012
Wednesday, June 20, 2012 - 1:21pm | 686Listed below are today's Top Downgrades covered by Benzinga: Citigroup Downgrades HSN (NASDAQ: HSNI) to Neutral: Citigroup notes, "We rate HSN Neutral (2). Despite potential to accelerate buybacks and solid operating performance, we see only modest upside from current levels. …Our $42.50 target...
-
UPDATE: Brean Murray Carret Downgrades CH Energy Group to Sell on Probability of Sale to Fortis
Wednesday, June 20, 2012 - 8:00am | 94Brean Murray Carret reduces its rating on CH Energy Group (NYSE: CHG) from Hold to Sell, while keeping the price target at $65. Brean Murray Carret comments, "We are lowering our rating to Sell with a target price of $65, based on the higher probability the company is sold to Fortis, given the...
-
Three Winning Analyst Rating Trades for June 14
Thursday, June 14, 2012 - 3:47pm | 370Traders looking for equities with high-probability moves in an Up or Down direction should look no further than analyst rating changes. Stocks being reported with new ratings equivalent to "Buy" - such as upgrades to Overweight or initiations with Outperform - have a notable propensity for upward...
-
Benzinga's Initiation Summary for June 14, 2012
Thursday, June 14, 2012 - 12:21pm | 490Listed below are today's Top Initiations covered by Benzinga: Global Hunter Securities Initiates CAI International (NYSE: CAP) with Accumulate rating, $21 PT: Global Hunter Securities comments, "As one of several public container leasing companies, we believe that CAI International (CAP)...
-
UPDATE: Brean Murray Carret Initiates Coverage on Ventrus Biosciences
Thursday, June 14, 2012 - 9:54am | 174Brean Murray Carret and Co. initiates coverage of Ventrus Biosciences (NASDAQ: VTUS) at a Buy rating and a price target of $30. Brean Murray Carret and Co. comments, “We are initiating coverage of Ventrus Biosciences Inc. with a Buy rating, as we believe that VEN 309 has blockbuster potential,...
-
UPDATE: Brean Murray Carret Initiates Buy, $30 PT on Ventrus Biosciences Ahead of VEN 309 Clinical Results
Thursday, June 14, 2012 - 8:06am | 142Brean Murray Carret initiates its coverage on Ventrus Biosciences (NASDAQ: VTUS) with a Buy rating and a price target of $30. Brean Murray Carret comments, "We are initiating coverage of Ventrus Biosciences Inc. with a Buy rating, as we believe that VEN 309 has blockbuster potential, given its...
-
UPDATE: Brean Murray Carret Reiterates Buy, $16 PT on Dell; Undervalued Asset
Thursday, June 14, 2012 - 7:49am | 126Brean Murray Carret reiterates its Buy rating and $16 price target on Dell (NASDAQ: DELL) amid a softening PC environment. Brean Murray Carret notes, "We continue to view Dell as an undervalued asset (see our sum of the parts in Figures 2 & 3), while also acknowledging N‐T catalysts are tough...
-
Benzinga's Initiation Summary for May 31, 2012
Thursday, May 31, 2012 - 12:42pm | 982Listed below are today's Top Initiations at Benzinga: Global Hunter Securities Initiates Arch Coal (NYSE: ACI) at Neutral: Global Hunter Securities said, "We are initiating coverage on ACI with a Neutral rating. We project that ACI will lose money the next 3-6 quarters. Based on its average EV/...
-
Slippery May Sales for Wet Seal
Thursday, May 31, 2012 - 8:15am | 563These days, retail stores are either experiencing some of the best fiscal years in history or are operating much like they are still feeling the pangs of the recession. For a lucky few, like Rue21 (NASDAQ: RUE) and dELiA*s (NASDAQ: DLIA), sales have increased in the first quarter with hopeful...
-
Brean Murray Carret Reiterates Buy, $20 PT on Pitney Bowes on Cash Flow Confidence
Thursday, May 31, 2012 - 7:34am | 94Brean Murray Carret maintains its Buy rating and $20 price target on Pitney Bowes (NYSE: PBI). Brean Murray Carret notes, "Pitney continues feels comfortable in its ability to generate adequate cash to pay its dividend (~$300M), handle debt obligations and fund growth initiatives. PBI believes in...
-
Benzinga's Top Downgrades With Color for May 24, 2012
Thursday, May 24, 2012 - 9:44am | 363Listed below are today's Top pre-market Downgrades at Benzinga: Brean Murray Carret Downgrades NetApp (NASDAQ: NTAP) to Hold: Brean Murray Carret notes, "We're moving to Hold from Buy for now as the July Q revenue softness we spoke of in our preview is substantially greater than we'd envisioned...